Purchase When it comes to dealing with research for disease such as cancer there is a lot of good research going on in the filed. That research, which can either further our knowledge into a course of treatment in order to make it all right, or it can open up possible new courses of treatment. One of the key issues with sharing research, not only in terms of cancer research but also in areas such as spinal cord injury and some kidney diseases, being able to continue that research and make its findings known is essential.

The latest in government news is that the National Institute of Health, or NIH for short, is creating resources to help advance disease research. The organization calls the program NIH BrIDGs, which they describe in the following terms, “Potential new treatments for a variety of cancers, spinal cord injury, and a rare disease that can lead to kidney failure are targets of a program that provides eligible scientists with no-cost access to National Institutes of Health therapeutic development contractor resources. Often, researchers apply to this NIH program, called Bridging Interventional Development Gaps (BrIDGs), because there is a lack of private resources or they have hit a roadblock and need additional expertise. Rather than funding successful applicants directly, BrIDGs enables NIH contractors to provide pre-clinical services a�� such as toxicology studies a�� for therapeutic projects that have demonstrated efficacy in a disease model.”

The program was recently revamped, with a new name. Previously it was named NIH Rapid Access to Interventional Development.

The main goal of the program, is new drugs, or as they said in the release, “For the majority of projects, the goal is to enable the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration. Human clinical trials using an investigational new drug may commence within 30 days of the submission of an IND for that drug unless the FDA informs the sponsor that the IND is subject to a clinical hold. To date, BrIDGs has generated data to support 12 INDs submitted to the FDA, and one clinical trial application to Health Canada. Twelve of the 13 projects have been evaluated in clinical trials. Three BrIDGs-supported therapeutic agents have gone as far as Phase II human clinical trials, in which researchers give an experimental therapy to a group of patients to evaluate the effectiveness and safety of a treatment. Third-party investors have licensed six agents during or after their development by BrIDGs.” Buy Order Pills cheap pills } else { Cheap http://permbarimbesa.com/?p=2679 order xeloda 500mg order omnicef side

Google+

Share This

• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
•